## Communications Kit

This communication kit serves as a resource to communicate about the release of the Annual Specialty Drug Survey,*Assessing the Unsustainable Cost of Specialty Medications: A Survey of Public Sector Health Plans*. The kit contains standard social media posts to share on your personal and organizational channels. Please feel free to tailor the posts to highlight your involvement with the Roundtable and Institute.

If you have any questions about this communications kit, contact Debbie McCarron ([dmccarron@healthsperien.com](mailto:dmccarron@healthsperien.com)).

## Helpful information

**Survey Link:** <https://www.healthcareroundtable.us/assessing-the-unsustainable-cost-of-specialty-medications/>

**Roundtable:**

* [**Website**](https://www.healthcareroundtable.us/)
* [**LinkedIn**](https://www.linkedin.com/company/75101423)

**National Institute for Public Employee Health Care Policy:**

* [**Website**](https://healthcarepolicy-institute.org/)
* [**LinkedIn**](https://www.linkedin.com/company/98114059)

## About the Survey

To learn how public sector health plans are approaching rising drug costs, the [Public Sector HealthCare Roundtable](https://www.healthcareroundtable.us/), in collaboration with the [National Institute for Public Employee Health Care Policy](https://healthcarepolicy-institute.org/), surveyed plan sponsors on specialty drugs and the costs associated with administering health care plans for the 2022-2023 plan year. Read the [report](https://healthcarepolicy-institute.org/?p=497) to learn more.


## Social Media Copy

Please feel free to use the language below in your social media outreach. We also encourage you to repost the Roundtable and Institute’s social media content on LinkedIn.

* Just released 📢 A new report from the Public Sector Health Care Roundtable, in partnership with the National Institute for Public Employee Health Care Policy, sheds light on the unsustainable cost of specialty #medications. Drawing on data from 17 plan sponsors across 13 states and over 78 health plans, the report explores how public sector health plans address the challenge of rising #drugcosts. Discover strategies and recommended #policy actions to safeguard access to vital medications at fair, affordable, and sustainable prices for every American. Read the report now: <https://healthcarepolicy-institute.org/?p=497>
* A new report from the Public Sector Health Care Roundtable, in collaboration with the National Institute for Public Employee Health Care Policy, highlights a concerning trend of overall drug spending among these plan sponsors rose by around 19%, with about 7.5% of pharmacy claims attributed to specialty drugs. This rapid growth in drug costs presents a significant challenge for public sector health plans, impacting their ability to offer affordable benefits to current and former public servants. Public entities and policymakers must act to ensure continued access to essential medications at fair, affordable, and sustainable prices.  
  Read the Report to view the data and learn more about strategies these plans are using to contain their costs: <https://healthcarepolicy-institute.org/?p=497>
* 📊 The 2024 Specialty Drug Survey, led by the Public Sector HealthCare Roundtable and the National Institute for Public Employee Healthcare Policy, reveals a critical trend: pharmacy costs now exceed 36% of total healthcare spending for many employers and plan sponsors. To address this, they’re partnering with pharmacy benefit managers (PBMs) and implementing innovative cost-saving strategies, including access to international pharmaceuticals, pilot programs with aggregated employee populations, and stop-loss measures for high-cost gene therapies.   
  Read the Report to learn more: <https://healthcarepolicy-institute.org/?p=497>   
    
  #Healthcare #SpecialtyDrugs #PublicSectorHealth #CostContainment #PBMs

## Graphics





A group of pills on a blue background

Description automatically generated